Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases
Key Highlights
- ➤Revuforj wins 2026 Prix Galien USA award for Best Product for Rare/Orphan Diseases
- ➤Revuforj is FDA-approved for patients one year and older with R/R acute leukemia
- ➤FDA expanded Revuforj approval to NPM1-mutated R/R AML in October 2025
- ➤Revuforj clinical trials reported differentiation syndrome in 25% of treated patients
- ➤Revuforj clinical trials reported QTc interval prolongation in 36% of treated patients
Expert Statements
Peter Ordentlich, Chief Scientific Officer and Founder of Syndax
“We are honored to receive this prestigious award from The Galien Foundation that recognizes the groundbreaking science behind Revuforj and its transformational impact on the treatment paradigm for relapsed or refractory KMT2A-translocated and NPM1-mutated acute leukemias,”
Peter Ordentlich, Chief Scientific Officer and Founder of Syndax
“We share this recognition with the many patients, scientists, clinicians, and Syndax team members whose tireless dedication made it possible for us to bring a new type of targeted treatment to adults and children battling some of the most aggressive forms of acute leukemia.”
- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia -
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj(®) (revumenib) has been recognized as the Best Product for Rare/Orphan Diseases of 2026 by The Galien Foundation. The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve human health.
Get started
Create a free account to read the full story.